Insmed Incorporated Investor Presentation

Insmed is a biopharmaceutical company developing and commercializing therapies for serious lung diseases. The company markets ARIKAYCE (amikacin liposome inhalation suspension) for mycobacterium avium complex lung disease and is advancing clinical candidates including brensocatib and TPIP.